Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
企業コードVCYT
会社名Veracyte Inc
上場日Oct 30, 2013
最高経営責任者「CEO」Mr. Marc A. Stapley
従業員数824
証券種類Ordinary Share
決算期末Oct 30
本社所在地6000 Shoreline Court, Suite 300
都市SOUTH SAN FRANCISCO
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号94080
電話番号16502436300
ウェブサイトhttps://www.veracyte.com/
企業コードVCYT
上場日Oct 30, 2013
最高経営責任者「CEO」Mr. Marc A. Stapley
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし